Dr. Ben Van Handel is an accomplished stem cell scientist and entrepreneur with a proven track record of bringing innovative therapies to market. As the co-founder of Carthronix, he recently led the company to a key milestone: the FDA clearance of the CX-011 osteoarthritis IND, advancing its lead therapeutic program into clinical trials.

An award-winning researcher, Dr. Van Handel has authored over 60 papers on regenerative medicine and stem cell biology, which have been cited more than 5,000 times. He holds a B.S. in Biochemistry from Northern Michigan University and a Ph.D. in Molecular, Cell, and Developmental Biology from UCLA. Dr. Van Handel has also founded three companies, serving as CEO for each, and has successfully raised significant capital.